Loading...
Market
Who will be the first major competitor to launch a non-immunosuppressive IgA nephropathy treatment after FILSPARI's approval?
2
Resolution / Starting Odds
Novartis • 25%
Calliditas • 25%
Ligand Partner • 25%
Other • 25%
Official announcements or press releases from the respective companies
Story
FDA Grants Full Approval to Travere Therapeutics' FILSPARI for IgA Nephropathy, Stock Rises 5.7%
Sep 6, 2024, 01:22 PM
The FDA has granted full approval to Travere Therapeutics' drug FILSPARI (sparsentan), marking it as the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgA nephropathy (IgAN). This approval follows a conversion from an accelerated approval and comes with an expanded label. The decision has positively impacted Travere's stock, which saw a 5.7% increase in pre-market trading. The approval is expected to intensify competition with Novartis and Calliditas in the kidney disease treatment market. Ligand Partner is also associated with this approval.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
GlaxoSmithKline • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%